PMID- 22089392
OWN - NLM
STAT- MEDLINE
DCOM- 20130108
LR  - 20161020
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 22
IP  - 4
DP  - 2012 Aug
TI  - High serum matrix metalloproteinase 3 is characteristic of patients with 
      paraneoplastic remitting seronegative symmetrical synovitis with pitting edema 
      syndrome.
PG  - 584-8
LID - 10.1007/s10165-011-0556-y [doi]
AB  - Recently, it was reported that remitting seronegative symmetrical synovitis with 
      pitting edema (RS3PE) syndrome could be complicated with solid tumors. In a 
      retrospective, multicenter study between October, 2003 and September, 2010, we 
      investigated the characteristics of patients with paraneoplastic RS3PE syndrome 
      who fulfilled following criteria: (1) bilateral pitting edema of hands or feet or 
      both, (2) sudden onset of polyarthritis, and (3) age >50 years, (4) 
      seronegativity for rheumatoid factor (RF). A total of 33 cases fulfilled the 
      above criteria. Eight patients (seven men and one woman) developed cancer within 
      2 years of RS3PE syndrome onset. There was no significant difference between the 
      neoplastic and nonneoplastic groups in the proportions of patients with fever, 
      symmetrical polyarthritis, pitting edema, and good response to corticosteroids. 
      Serum matrix metalloproteinase 3 (MMP-3) level (median 437.3 ng/ml) in the 
      paraneoplastic RS3PE patients was significantly higher than that in patients 
      without neoplasia (median 114.7 ng/ml) (p < 0.05). We found that high serum MMP-3 
      is characteristic of patients with paraneoplastic RS3PE syndrome.
FAU - Origuchi, Tomoki
AU  - Origuchi T
AD  - Department of Rehabilitation Sciences, Graduate School of Biomedical Sciences, 
      Nagasaki University, 1-7-1 Sakamoto, Nagasaki, 852-8520, Japan. 
      origuchi@nagasaki-u.ac.jp
FAU - Arima, Kazuhiko
AU  - Arima K
FAU - Kawashiri, Shin-Ya
AU  - Kawashiri SY
FAU - Tamai, Mami
AU  - Tamai M
FAU - Yamasaki, Satoshi
AU  - Yamasaki S
FAU - Nakamura, Hideki
AU  - Nakamura H
FAU - Tsukada, Toshiaki
AU  - Tsukada T
FAU - Aramaki, Toshiyuki
AU  - Aramaki T
FAU - Furuyama, Masako
AU  - Furuyama M
FAU - Miyashita, Taiichiro
AU  - Miyashita T
FAU - Kawabe, Yojiro
AU  - Kawabe Y
FAU - Iwanaga, Nozomi
AU  - Iwanaga N
FAU - Terada, Kaoru
AU  - Terada K
FAU - Ueki, Yukitaka
AU  - Ueki Y
FAU - Fukuda, Takaaki
AU  - Fukuda T
FAU - Eguchi, Katsumi
AU  - Eguchi K
FAU - Kawakami, Atsushi
AU  - Kawakami A
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20111117
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Biomarkers)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthritis/blood/complications/diagnosis
MH  - Biomarkers/blood
MH  - Edema/*blood/complications/diagnosis
MH  - Extremities
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Paraneoplastic Syndromes/*blood/complications/diagnosis
MH  - Retrospective Studies
MH  - Rheumatoid Factor/blood
MH  - Serologic Tests
MH  - Synovitis/*blood/complications/diagnosis
EDAT- 2011/11/18 06:00
MHDA- 2013/01/09 06:00
CRDT- 2011/11/18 06:00
PHST- 2011/08/04 00:00 [received]
PHST- 2011/10/31 00:00 [accepted]
PHST- 2011/11/18 06:00 [entrez]
PHST- 2011/11/18 06:00 [pubmed]
PHST- 2013/01/09 06:00 [medline]
AID - 10.1007/s10165-011-0556-y [doi]
PST - ppublish
SO  - Mod Rheumatol. 2012 Aug;22(4):584-8. doi: 10.1007/s10165-011-0556-y. Epub 2011 
      Nov 17.